Introduction, PART I: The Use and Supply of Doping Products, 1. Assessing and Explaining the Doping Prevalence in Cycling, 2. Changing Patterns of Drug Use in Professional Cycling: Implications for Anti-Doping Policy, 3. Substance Use, Anti-Doping, and Health in Amateur Cycling, 4. The Impact of Scientific Advances on Doping in Cycling, 5. Kicked Out: How Experts Are Being Deterred from Playing on the Doping Market, 6. The Peculiarities of the Market For Doping Products and the Role of Academic Physicians, PART II: Threats on Cycling and Opportunities for Anti-Doping, 7. Doped Humans and Rigged Bikes - And Why We (Wrongly) Get More Upset About the Bikes, 8. Everyone Was Doing It: Applying Lessons from Cycling's EPO Era to a Looming TUE Era, 9. Cycling Teams Preventing Doping: Can the Fox Guard the Hen House?, 10. Blowing the Whistle on Doping in Cycling, 11. Performance Data to Improve Cycling's Credibility?, 12. What Might a Partially Relaxed Anti-Doping Regime in Professional Cycling Look Like?, PART III: Issues, Controversies and Stakes, 13. The Decline of Trust in British Sport Since the London Olympics: Team Sky's Fall from Grace, 14. Is Froome's Performance on the 2015 Tour de France Credible? A Sociological Analysis of the Construction of the Performance's Authenticity in Cycling, 15. The Clean Corrective: Can Thinking About Clean Cyclists Enhance Anti-Doping?, 16. What to do with the TUE Process? Bradley Wiggins, Therapeutic Use and Data Sharing: A Critical Analysis, 17. Doping Relevance and the World Anti-Doping Code
